69839-83-4

中文名称 3,4-二羟基苯甲羟肟酸

英文名称 dido

CAS 69839-83-4

分子式 C7H7NO4

分子量 169.13

MOL 文件 69839-83-4.mol

更新日期 2024/05/13 11:03:39

69839-83-4 结构式

基本信息物理化学性质安全数据图谱信息 3,4-二羟基苯甲羟肟酸价格(试剂级) 常见问题列表

基本信息

中文别名

4-二羟基苯甲羟肟酸
3,4-二羟基苯甲羟肟酸

英文别名

dido
Didox
NSC-324360
Didox, NSC-324360
Didox Exclusive
4-Trihydroxybenzamide
N,3,4-trihydroxybenzamide
Benzamide, N,3,4-trihydroxy-
3,4-dihydroxybenzohydroxamic acid

所属类别

生物化工：激动剂抑制剂

物理化学性质

熔点207 °C

密度1.571±0.06 g/cm3(Predicted)

储存条件Inert atmosphere,Store in freezer, under -20°C

溶解度DMSO:60.0(Max Conc. mg/mL);354.76(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);118.25(Max Conc. mM)
Ethanol:20.0(Max Conc. mg/mL);118.25(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);59.13(Max Conc. mM)

酸度系数(pKa)8.16±0.20(Predicted)

形态结晶固体

安全数据

毒性LD10 unreported in mouse: 643mg/kg

图谱信息

3,4-二羟基苯甲羟肟酸(69839-83-4)核磁图(¹HNMR)

3,4-二羟基苯甲羟肟酸价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-19387	3,4-二羟基苯甲羟肟酸 Didox	69839-83-4	5mg	600元
2024/04/30	HY-19387	3,4-二羟基苯甲羟肟酸 Didox	69839-83-4	10mM * 1mLin DMSO	660元
2024/04/30	HY-19387	3,4-二羟基苯甲羟肟酸 Didox	69839-83-4	10mg	800元

常见问题列表

生物活性

Didox (NSC-324360) 是一种合成的核糖核苷酸还原酶 (ribonucleotide reductase, RR) 抑制剂。

靶点

Ribonucleotide reductase

体外研究

Didox (NSC-324360) suppresses LPS-induced mRNA levels of iNOS, IL-6, IL-1, TNF-α, NF-κβ (p65), and p38-α, after 24 h of treatment. Treatment with Didox also suppresses the secretion of nitric oxide (NO), IL-6, and IL-10. Using mitochondrial dehydrogenase activity as a measure of cytotoxicity, the effects of Didox on cellular respiration in RAW264.7 are examined over a range of concentrations for 24 h. Cells exposures to 200 μM and below Didox, with and without LPS, do not exhibit significant cellular toxicity. Didox (NSC-324360) is active against all human and murine acute myeloid leukemia (AML) lines tested with IC ₅₀ values in the low micromolar range (mean IC ₅₀ 37 µM [range 25.89-52.70 µM]).

体内研究

Once engraftment is established by bioluminescent imaging, the animals receive daily administrations of Didox at 425 mg/kg via IP injection over 5 days. Didox (NSC-324360) treatment significantly reduces leukemic burden compared to vehicle treated controls (p=0.0026 and p=0.0342). More importantly, Didox (NSC-324360) provides a significant survival benefit (p<0.0001 and p=0.0094).